Evidence map›Paper›PMID 35721081›Full record

ArticleFrontiers in medicine2022

Delayed Impact of 2-Oxoadipate Dehydrogenase Inhibition on the Rat Brain Metabolism Is Linked to Protein Glutarylation.

Alexandra I Boyko, Irina S Karlina, Lev G Zavileyskiy, Vasily A Aleshin, Artem V Artiukhov, Thilo Kaehne, Alexander L Ksenofontov, Sergey I Ryabov, Anastasia V Graf, Angela Tramonti and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Alexandra I BoykoFaculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, Moscow, Russia.
Irina S KarlinaN.V. Sklifosovsky Institute of Clinical Medicine, Sechenov First Moscow State Medical University, Moscow, Russia.
Lev G ZavileyskiyFaculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, Moscow, Russia.
Vasily A AleshinBelozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow, Russia.
Artem V ArtiukhovBelozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow, Russia.
Thilo KaehneInstitute of Experimental Internal Medicine, Otto von Guericke University Magdeburg, Magdeburg, Germany.
Alexander L KsenofontovBelozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow, Russia.
Sergey I RyabovRussian Cardiology Research and Production Complex, Ministry of Health of the Russian Federation, Moscow, Russia.
Anastasia V GrafBelozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow, Russia.
Angela TramontiInstitute of Molecular Biology and Pathology, Council of National Research, Department of Biochemical Sciences "A. Rossi Fanelli", Sapienza University, Rome, Italy.
Victoria I BunikFaculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, Moscow, Russia.
Lomonosov Moscow State University · RUInstitute of Molecular Biology and Pathology · ITMinistry of Health of the Russian Federation · RUOtto-von-Guericke University Magdeburg · DESechenov University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The Methods: The weight-drop model of SCI, a single intranasal administration of an OADH-directed inhibitor trimethyl adipoyl phosphonate (TMAP), and quantification of the associated metabolic changes in the rat brain employ established methods. Results: The TMAP-induced metabolic changes in the brain of the control, laminectomized (LE) and SCI rats are long-term and (patho)physiology-dependent. Increased glutarylation of the brain proteins, proportional to OADH expression in the control and LE rats, represents a long-term consequence of the OADH inhibition. The proportionality suggests autoglutarylation of OADH, supported by our mass-spectrometric identification of glutarylated K155 and K818 in recombinant human OADH. In SCI rats, TMAP increases glutarylation of the brain proteins more than OADH expression, inducing a strong perturbation in the brain glutathione metabolism. The redox metabolism is not perturbed by TMAP in LE animals, where the inhibition of OADH increases expression of deglutarylase sirtuin 5. The results reveal the glutarylation-imposed control of the brain glutathione metabolism. Glutarylation of the ODP2 subunit of pyruvate dehydrogenase complex at K451 is detected in the rat brain, linking the OADH function to the brain glucose oxidation essential for the redox state. Short-term inhibition of OADH by TMAP administration manifests in increased levels of tryptophan and decreased levels of sirtuins 5 and 3 in the brain. Conclusion: Pharmacological inhibition of OADH affects acylation system of the brain, causing long-term, (patho)physiology-dependent changes in the expression of OADH and sirtuin 5, protein glutarylation and glutathione metabolism. The identified glutarylation of ODP2 subunit of pyruvate dehydrogenase complex provides a molecular mechanism of the OADH association with diabetes.

Indexed as

2-oxoadipate dehydrogenasecitrullineDHTKD1glutarylationglutathionephosphonate analog of 2-oxoadipatesirtuin 5

Identifiers

PMID35721081
PMCPMC9198357
OpenAlexW4281862323

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.